Anti-leukemic immunity against U937 cells in uremic patients

C. J. Wu, J. R. Sheu, H. H. Chen, S. D. Shyur, P. G. Chen, Y. J. Chen

Research output: Contribution to journalArticle

Abstract

To examine anti-tumor immunity in uremic patients undergoing regular hemodialysis, we designed this study using in vitro mononuclear cell (MNC) cultures, with human leukemic U937 cells as the target. MNC were collected and cultured from uremic subjects and age- and gender-matched healthy controls. Conditioned media from the cultures (MNC-CM) were collected after stimulation with various concentrations of phytohemagglutinin (PHA). The proliferation-inhibiting and differentiation-inducing activities of the PHA-MNC-CM on U937 cells were evaluated. The growth inhibition activity of uremic patients' PHA -MNC-CM was lower than that of controls. The differentiation-inducing effects were evaluated by morphological scoring, superoxide production, and monocyte-associated antigen expression (CD14 and CD68). All three parameters demonstrated that the differentiation-inducing effect of MNC-CM increased with increasing doses of PHA. These effects, however, were significantly less in uremic patients compared to controls at higher doses of PHA. The levels of TNF-α and IFN-γ in PHA-MNC-CM increased in a PHA dose-dependent manner and were much higher in the controls. We conclude that the capacity of MNC from uremic hemodialysis patients to produce anti-leukemic immunity is significantly lower than that of healthy controls.

Original languageEnglish
Pages (from-to)54-59
Number of pages6
JournalNeoplasma
Volume50
Issue number1
Publication statusPublished - 2003

Fingerprint

U937 Cells
Phytohemagglutinins
Immunity
Renal Dialysis
CD14 Antigens
Conditioned Culture Medium
Superoxides
Monocytes
Cell Culture Techniques
Growth

Keywords

  • Differentiation
  • Leukemic U937 cell
  • Proliferation
  • Uremia

ASJC Scopus subject areas

  • Cancer Research

Cite this

Wu, C. J., Sheu, J. R., Chen, H. H., Shyur, S. D., Chen, P. G., & Chen, Y. J. (2003). Anti-leukemic immunity against U937 cells in uremic patients. Neoplasma, 50(1), 54-59.

Anti-leukemic immunity against U937 cells in uremic patients. / Wu, C. J.; Sheu, J. R.; Chen, H. H.; Shyur, S. D.; Chen, P. G.; Chen, Y. J.

In: Neoplasma, Vol. 50, No. 1, 2003, p. 54-59.

Research output: Contribution to journalArticle

Wu, CJ, Sheu, JR, Chen, HH, Shyur, SD, Chen, PG & Chen, YJ 2003, 'Anti-leukemic immunity against U937 cells in uremic patients', Neoplasma, vol. 50, no. 1, pp. 54-59.
Wu CJ, Sheu JR, Chen HH, Shyur SD, Chen PG, Chen YJ. Anti-leukemic immunity against U937 cells in uremic patients. Neoplasma. 2003;50(1):54-59.
Wu, C. J. ; Sheu, J. R. ; Chen, H. H. ; Shyur, S. D. ; Chen, P. G. ; Chen, Y. J. / Anti-leukemic immunity against U937 cells in uremic patients. In: Neoplasma. 2003 ; Vol. 50, No. 1. pp. 54-59.
@article{8c9b1ee04b6045bdb3302bf243084daa,
title = "Anti-leukemic immunity against U937 cells in uremic patients",
abstract = "To examine anti-tumor immunity in uremic patients undergoing regular hemodialysis, we designed this study using in vitro mononuclear cell (MNC) cultures, with human leukemic U937 cells as the target. MNC were collected and cultured from uremic subjects and age- and gender-matched healthy controls. Conditioned media from the cultures (MNC-CM) were collected after stimulation with various concentrations of phytohemagglutinin (PHA). The proliferation-inhibiting and differentiation-inducing activities of the PHA-MNC-CM on U937 cells were evaluated. The growth inhibition activity of uremic patients' PHA -MNC-CM was lower than that of controls. The differentiation-inducing effects were evaluated by morphological scoring, superoxide production, and monocyte-associated antigen expression (CD14 and CD68). All three parameters demonstrated that the differentiation-inducing effect of MNC-CM increased with increasing doses of PHA. These effects, however, were significantly less in uremic patients compared to controls at higher doses of PHA. The levels of TNF-α and IFN-γ in PHA-MNC-CM increased in a PHA dose-dependent manner and were much higher in the controls. We conclude that the capacity of MNC from uremic hemodialysis patients to produce anti-leukemic immunity is significantly lower than that of healthy controls.",
keywords = "Differentiation, Leukemic U937 cell, Proliferation, Uremia",
author = "Wu, {C. J.} and Sheu, {J. R.} and Chen, {H. H.} and Shyur, {S. D.} and Chen, {P. G.} and Chen, {Y. J.}",
year = "2003",
language = "English",
volume = "50",
pages = "54--59",
journal = "Neoplasma",
issn = "0028-2685",
publisher = "Vydavatel'stvo Slovenkej Akademie Vied/Veda Publishing House of the Slovak Academy of Sciences",
number = "1",

}

TY - JOUR

T1 - Anti-leukemic immunity against U937 cells in uremic patients

AU - Wu, C. J.

AU - Sheu, J. R.

AU - Chen, H. H.

AU - Shyur, S. D.

AU - Chen, P. G.

AU - Chen, Y. J.

PY - 2003

Y1 - 2003

N2 - To examine anti-tumor immunity in uremic patients undergoing regular hemodialysis, we designed this study using in vitro mononuclear cell (MNC) cultures, with human leukemic U937 cells as the target. MNC were collected and cultured from uremic subjects and age- and gender-matched healthy controls. Conditioned media from the cultures (MNC-CM) were collected after stimulation with various concentrations of phytohemagglutinin (PHA). The proliferation-inhibiting and differentiation-inducing activities of the PHA-MNC-CM on U937 cells were evaluated. The growth inhibition activity of uremic patients' PHA -MNC-CM was lower than that of controls. The differentiation-inducing effects were evaluated by morphological scoring, superoxide production, and monocyte-associated antigen expression (CD14 and CD68). All three parameters demonstrated that the differentiation-inducing effect of MNC-CM increased with increasing doses of PHA. These effects, however, were significantly less in uremic patients compared to controls at higher doses of PHA. The levels of TNF-α and IFN-γ in PHA-MNC-CM increased in a PHA dose-dependent manner and were much higher in the controls. We conclude that the capacity of MNC from uremic hemodialysis patients to produce anti-leukemic immunity is significantly lower than that of healthy controls.

AB - To examine anti-tumor immunity in uremic patients undergoing regular hemodialysis, we designed this study using in vitro mononuclear cell (MNC) cultures, with human leukemic U937 cells as the target. MNC were collected and cultured from uremic subjects and age- and gender-matched healthy controls. Conditioned media from the cultures (MNC-CM) were collected after stimulation with various concentrations of phytohemagglutinin (PHA). The proliferation-inhibiting and differentiation-inducing activities of the PHA-MNC-CM on U937 cells were evaluated. The growth inhibition activity of uremic patients' PHA -MNC-CM was lower than that of controls. The differentiation-inducing effects were evaluated by morphological scoring, superoxide production, and monocyte-associated antigen expression (CD14 and CD68). All three parameters demonstrated that the differentiation-inducing effect of MNC-CM increased with increasing doses of PHA. These effects, however, were significantly less in uremic patients compared to controls at higher doses of PHA. The levels of TNF-α and IFN-γ in PHA-MNC-CM increased in a PHA dose-dependent manner and were much higher in the controls. We conclude that the capacity of MNC from uremic hemodialysis patients to produce anti-leukemic immunity is significantly lower than that of healthy controls.

KW - Differentiation

KW - Leukemic U937 cell

KW - Proliferation

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=0347078311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347078311&partnerID=8YFLogxK

M3 - Article

C2 - 12687279

AN - SCOPUS:0347078311

VL - 50

SP - 54

EP - 59

JO - Neoplasma

JF - Neoplasma

SN - 0028-2685

IS - 1

ER -